Case Fatalities in Hospitalised COVID-19 Patients in the UK
Completed
- Conditions
- Covid19
- Registration Number
- NCT04527458
- Lead Sponsor
- University of Edinburgh
- Brief Summary
This study will investigate how the case fatality in hospitalised patients with COVID-19 has changed throughout the pandemic. It will also explore possible mechanisms that could be driving these changes. This analysis will enhance our understanding of the virus, which will be important for researchers and clinicians to respond appropriately.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 70000
Inclusion Criteria
- All patients admitted with a proven or high likelihood of COVID-19
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Case fatality 23 weeks The proportion of new admissions with COVID-19 who died over time
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive changes in case fatality rates for hospitalized COVID-19 patients in the UK as analyzed in NCT04527458?
How do emerging SARS-CoV-2 variants impact patient outcomes in the ISARIC NCT04527458 observational study?
What biomarkers correlate with survival in NCT04527458 hospitalized patients receiving antiviral therapies?
What are the comparative effectiveness of corticosteroids and IL-6 inhibitors in reducing mortality for hospitalized COVID-19 patients as per NCT04527458?
What adverse events are associated with dexamethasone use in severe COVID-19 cases within the NCT04527458 study cohort?
Trial Locations
- Locations (1)
University of Edinburgh
🇬🇧Edinburgh, United Kingdom
University of Edinburgh🇬🇧Edinburgh, United Kingdom